These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27392483)

  • 1. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stearoyl-CoA desaturase-1 is required for flavivirus RNA replication.
    Hishiki T; Kato F; Nio Y; Watanabe S; Wen Tan NW; Yamane D; Miyazaki Y; Lin CC; Suzuki R; Tajima S; Lim CK; Saijo M; Hijikata M; Vasudevan SG; Takasaki T
    Antiviral Res; 2019 May; 165():42-46. PubMed ID: 30853381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes.
    Lyn RK; Singaravelu R; Kargman S; O'Hara S; Chan H; Oballa R; Huang Z; Jones DM; Ridsdale A; Russell RS; Partridge AW; Pezacki JP
    Sci Rep; 2014 Apr; 4():4549. PubMed ID: 25008545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of host metabolism as a target of new antivirals.
    Ikeda M; Kato N
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon.
    Ikeda M; Kato N
    J Pharmacol Sci; 2007 Oct; 105(2):145-50. PubMed ID: 17928739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
    Munakata T; Inada M; Tokunaga Y; Wakita T; Kohara M; Nomoto A
    Antiviral Res; 2014 Aug; 108():79-87. PubMed ID: 24893207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
    Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
    Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle.
    Park SB; Boyer A; Hu Z; Le D; Liang TJ
    Antivir Ther; 2019; 24(5):371-381. PubMed ID: 30880685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
    Koutsoudakis G; Romero-Brey I; Berger C; Pérez-Vilaró G; Monteiro Perin P; Vondran FW; Kalesse M; Harmrolfs K; Müller R; Martinez JP; Pietschmann T; Bartenschlager R; Brönstrup M; Meyerhans A; Díez J
    J Hepatol; 2015 Oct; 63(4):813-21. PubMed ID: 26070407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.
    Oraby AK; Gardner CL; Needle RF; Kofahi HM; Everard KR; Taylor NGA; Rutihinda SG; Barry JP; Hirasawa K; Georghiou PE; Russell RS
    Microbiol Spectr; 2021 Sep; 9(1):e0043921. PubMed ID: 34319169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
    Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
    Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
    Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
    Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.
    Saito K; Shirasago Y; Suzuki T; Aizaki H; Hanada K; Wakita T; Nishijima M; Fukasawa M
    J Virol; 2015 Feb; 89(4):2220-32. PubMed ID: 25473062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage.
    Reddy BU; Mullick R; Kumar A; Sharma G; Bag P; Roy CL; Sudha G; Tandon H; Dave P; Shukla A; Srinivasan P; Nandhitha M; Srinivasan N; Das S
    Antiviral Res; 2018 Feb; 150():47-59. PubMed ID: 29224736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
    Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
    Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.